Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03860857 · ClinicalTrials.gov registry record · Phase 3
Biomarker Exploration in Aging, Cognition and Neurodegeneration
A Phase 3 study of Alzheimer Disease and Cognitive Impairment, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT03860857 is a Phase 3 study of Alzheimer Disease and Cognitive Impairment that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 300 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03860857, a Phase 3 study of Alzheimer Disease and Cognitive Impairment, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline. An addendum to this study includes additional PET scans to examine the relationship between tau protein in the brain and cognitive decline. Tau is a protein that is known to form tangles in the areas of the brain important for memory, and these tau tangles are a hallmark of Alzheimer's disease. This sub-study research aims to look at the tau accumulation in the brain using an investigational drug called MK-6240, which is a radio tracer that gets injected prior to a positron emission tomography (PET) scan.
Conditions Studied
Interventions
- OTHER MRI
- RADIATION Amyloid PET scan
- DRUG Tau PET scan using MK-6240
- BEHAVIORAL Neurocognitive testing
Study Locations (1)
California
- University of California, Irvine - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2027-12-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03860857
The ClinicalTrials.gov registry entry for NCT03860857 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (89% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 4 interventions - of which MRI is the first listed.
NCT03860857 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03860857 about?
NCT03860857 is a clinical study titled "Biomarker Exploration in Aging, Cognition and Neurodegeneration". The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline. An addendum to this...
What is the current status of trial NCT03860857?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2018-05-01. Estimated completion is 2027-12-22.
What conditions does trial NCT03860857 study?
This clinical trial studies the following conditions: Alzheimer Disease, Cognitive Impairment, Cognitive Decline.
What interventions are being tested in trial NCT03860857?
The interventions under investigation include: MRI (OTHER), Amyloid PET scan (RADIATION), Tau PET scan using MK-6240 (DRUG), Neurocognitive testing (BEHAVIORAL).
Who is sponsoring clinical trial NCT03860857?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03860857 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Epidemiology and Biomarker Study in Alzheimer's Disease
RECRUITING · Phase 3
-
[18F]PI-2620 Phase 3 Histopathological Study
RECRUITING · Phase 3
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
RECRUITING · Phase 3
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
RECRUITING · Phase 3
-
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.